Ectin Research is active in biotechnology. The company specializes in research and development of drug candidates. The research is focused on developing drugs that aim to eliminate cancerous tumors in patients, with the greatest focus on the treatment of bladder cancer. In addition, the company intends to develop drugs for the treatment of breast, colorectal and prostate cancer cells.

Quotes for Ectin Research AB

Right Now

+/-
-0.027
%
-5,40%
Latest
0.473
High
0.5
Low
0.47
Volume
44 734
Turnover (SEK)
21 355
Market Value (MSEK)
6,0
Time (Latest trade)

Board

CEO

  • Anna Sjöblom-Hallén

Chairperson of the Board

  • Hans-Peter Ostler

Board

  • Anders Waas
  • Christer Edlund
  • Fredrik Andersson
  • Göran Gannedahl
  • Marie-Lois Ivarsson
  • Peter Falk

Largest Owners

Name Capital % Votes % Date
JRS Asset Management AB Client Account 11,69 5,35 2022-06-28
Futur Pension 4,67 2,13 2022-09-15
Avanza Pension 4,39 2,01 2022-06-28
Ivarsson Medical Research AB 4,33 19,62 2022-06-28
Christer Edlund 4,33 19,62 2022-06-28
Peter Falk 4,29 19,60 2022-06-28
Gerhard Dal 4,01 1,83 2021-08-03
Per Nilsson 4,01 1,83 2021-08-03
Fredrik Andersson 3,95 1,81 2022-04-12
Åke Andersson 3,85 1,76 2021-08-03
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2022-10-10 Extra bolagsstämma 2022

  • 2022-11-22 Delårsrapport 2022-Q3